These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 21972264)

  • 1. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
    Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa.
    Novitsky V; Wester CW; DeGruttola V; Bussmann H; Gaseitsiwe S; Thomas A; Moyo S; Musonda R; Van Widenfelt E; Marlink RG; Essex M
    AIDS Res Hum Retroviruses; 2007 Jul; 23(7):868-78. PubMed ID: 17678469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance-associated mutations in HIV-1 among patients failing first-line antiretroviral therapy.
    Saini S; Bhalla P; Gautam H; Baveja UK; Pasha ST; Dewan R
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(3):203-9. PubMed ID: 21990611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
    J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
    HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T].
    Mouroux M; Izopet J; Descamps D; Delaugerre C; Yvon-Groussin A; Angleraud F; Coutellier A; Bonmarchand M; Valantin MA; Matheron S; Agut H; Katlama C; Brun-Vezinet F; Calvez V
    Pathol Biol (Paris); 2000 Jun; 48(5):508-12. PubMed ID: 10949850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
    J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
    Avi R; Pauskar M; Karki T; Kallas E; Jõgeda EL; Margus T; Huik K; Lutsar I
    J Med Virol; 2016 Mar; 88(3):448-54. PubMed ID: 26291050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
    Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China.
    Liu L; Lu HZ; Henry M; Tamalet C
    J Med Virol; 2007 Oct; 79(10):1593-9. PubMed ID: 17705165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
    Lanier ER; Givens N; Stone C; Griffin P; Gibb D; Walker S; Tisdale M; Irlbeck D; Underwood M; St Clair M; Ait-Khaled M
    HIV Med; 2004 Nov; 5(6):394-9. PubMed ID: 15544690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
    Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
    PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.